Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

6.570 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN
From DJS Law Group
Via Business Wire
OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Top stock movements in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Dow Surges Over 300 Points; McDonald's Posts Weak Revenue
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q1 But Stock Drops 23.5%
Pharmaceutical company Organon (NYSE:OGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per share... 
Via StockStory
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Organon Reports Results for the First Quarter Ended March 31, 2025
From Organon & Co.
Via Business Wire
Organon (OGN) Q1 Earnings: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
3 Cash-Producing Stocks with Questionable Fundamentals
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
LGI Homes, Super Micro, Organon, Ibotta, and ManpowerGroup Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after investor sentiment improved on renewed optimism that the US-China trade conflict might be nearing a resolution. According to reports, Treasury... 
Via StockStory
Topics World Trade
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
From Organon & Co.
Via Business Wire
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
From Organon & Co.
Via Business Wire
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings?
Organon has gotten torched over the last six months - since October 2024, its stock price has dropped 29.4% to a new 52-week low of $12.79 per share. This was partly driven by its softer quarterly... 
Via StockStory
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
From Organon & Co.
Via Business Wire
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
 
Via Benzinga
High-Yield Healthcare: 3 Stocks With Strong Dividends
This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.